Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Dow
Medtronic
AstraZeneca
Colorcon
Boehringer Ingelheim

Last Updated: November 26, 2022

CLINICAL TRIALS PROFILE FOR VASCEPA


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Vascepa

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02113163 ↗ PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA Unknown status Thetis Pharmaceuticals LLC Phase 1 2014-03-01 The primary objective of the study is to contrast the pharmacokinetic profiles of metformin and EPA delivered separately as co-administered products (metformin hydrochloride or Glucophage and icosapent ethyl or Vascepa) and together as the solid dose form (metformin eicosapentaenoate or TP-101) under fasted and fed conditions. A secondary objective is to evaluate the safety and tolerability of single and repeat single doses of TP-101.
NCT02422446 ↗ Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects Terminated Brigham and Women's Hospital Phase 3 2015-04-01 This pilot trial seeks to obtain preliminary data on the effects of eicosapentaenoic acid (EPA) (4g/d) on endothelial function measured via endopat2000 after 12 weeks of intervention among adults with elevated triglycerides and type 2 diabetes.
NCT02719327 ↗ Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid Active, not recruiting University of Wisconsin, Madison Phase 2/Phase 3 2017-06-08 The number of Americans diagnosed with Alzheimer's disease (AD) is expected to triple by 2050. Compared to the general population, Veterans have a greater risk of AD, likely in part due to their increased incidence of traumatic brain injury, post-traumatic stress disorder, depression, and other vascular-related health issues. Based on available data, 423,000 new cases of AD are anticipated in Veterans by 2020. Thus, the discovery of effective therapies to prevent or delay the onset of AD in Veterans is critical. The goal of this study is to evaluate the efficacy of a purified form of the omega-3 fatty acid eicosapentaenoic acid (EPA) called icosapent ethyl (IPE), on improving brain blood flow, spinal fluid markers of AD pathology, and cognitive performance in middle-aged, cognitively-healthy Veterans with increased risk of AD. If IPE delays the onset of AD by even 5 years, the incidence of AD would be reduced by 50% in this population and could have a profound effect on Veteran quality of life and healthcare costs.
NCT02719327 ↗ Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid Active, not recruiting VA Office of Research and Development Phase 2/Phase 3 2017-06-08 The number of Americans diagnosed with Alzheimer's disease (AD) is expected to triple by 2050. Compared to the general population, Veterans have a greater risk of AD, likely in part due to their increased incidence of traumatic brain injury, post-traumatic stress disorder, depression, and other vascular-related health issues. Based on available data, 423,000 new cases of AD are anticipated in Veterans by 2020. Thus, the discovery of effective therapies to prevent or delay the onset of AD in Veterans is critical. The goal of this study is to evaluate the efficacy of a purified form of the omega-3 fatty acid eicosapentaenoic acid (EPA) called icosapent ethyl (IPE), on improving brain blood flow, spinal fluid markers of AD pathology, and cognitive performance in middle-aged, cognitively-healthy Veterans with increased risk of AD. If IPE delays the onset of AD by even 5 years, the incidence of AD would be reduced by 50% in this population and could have a profound effect on Veteran quality of life and healthcare costs.
NCT02781584 ↗ Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH) Completed Gilead Sciences Phase 2 2016-07-13 The primary objective of this study is to evaluate the safety and tolerability of selonsertib, firsocostat, cilofexor, fenofibrate and/or Vascepa┬« in adults with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vascepa

Condition Name

Condition Name for Vascepa
Intervention Trials
Hypertriglyceridemia 4
Cardiovascular Diseases 2
Eicosapentaenoic Acid 2
Endoscopic Surgery 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Vascepa
Intervention Trials
Hypertriglyceridemia 5
Colorectal Neoplasms 3
Diabetes Mellitus, Type 2 2
Cardiovascular Diseases 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Vascepa

Trials by Country

Trials by Country for Vascepa
Location Trials
United States 22
Canada 2
United Kingdom 2
New Zealand 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Vascepa
Location Trials
Massachusetts 4
California 3
Florida 2
Louisiana 2
Utah 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Vascepa

Clinical Trial Phase

Clinical Trial Phase for Vascepa
Clinical Trial Phase Trials
Phase 4 3
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Vascepa
Clinical Trial Phase Trials
Recruiting 7
Completed 4
Active, not recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vascepa

Sponsor Name

Sponsor Name for Vascepa
Sponsor Trials
Massachusetts General Hospital 2
Amarin Pharma Inc. 2
Amarin Corporation 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Vascepa
Sponsor Trials
Other 27
Industry 7
NIH 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Boehringer Ingelheim
Harvard Business School
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.